Oral Wegovy approved
The FDA has approved an oral form of semaglutide — described as the first GLP‑1 pill for chronic weight management — supported by Phase III OASIS 4 results showing substantial weight loss and cardiometabolic improvements. (appliedclinicaltrialsonline.com) Clinicians and coverage note that as GLP‑1s become more convenient, patients are advised to add strength training to protect muscle mass while losing weight. (indianexpress.com)
Wegovy is no longer only a weekly shot in the United States. The Food and Drug Administration approved Wegovy tablets, a once-daily semaglutide pill for adults with obesity or overweight plus a weight-related condition. (accessdata.fda.gov) Semaglutide is a hormone-mimicking drug that helps people feel fuller and eat less. The new tablet is approved with a reduced-calorie diet and increased physical activity, and it also carries a cardiovascular indication for adults with established heart disease and obesity or overweight. (wegovy.com) The approval followed the Phase 3 OASIS 4 trial, a 64-week study of 307 adults without diabetes. Patients assigned to oral semaglutide 25 milligrams lost 13.6% of body weight on average, versus 2.2% with placebo. (nejm.org) In a treatment-adherence analysis, average weight loss reached 16.6% with the pill, compared with 2.7% with placebo. Novo Nordisk said it planned a United States launch in early January 2026 after the December 22, 2025 approval. (prnewswire.com) The shift is practical as much as medical: a pill removes the needle, but not the long-term treatment model. The Food and Drug Administration label keeps the same boxed warning on thyroid C-cell tumors seen in rodents and says the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (accessdata.fda.gov) The tablet also comes with instructions that make it less simple than a standard pill. Coverage comparing the new products notes oral Wegovy must be taken on an empty stomach in the morning with up to 4 ounces of water, then followed by a 30-minute wait before eating. (managedhealthcareexecutive.com) Weight loss on these drugs is not only fat loss. Mayo Clinic says research suggests about 25% to 40% of weight lost during glucagon-like peptide-1 therapy may come from lean mass, which is why clinicians increasingly pair the drugs with protein intake and resistance exercise. (mayoclinic.com) A joint statement summarized by the National Education on Obesity Society says patients on glucagon-like peptide-1-based therapy should get baseline checks of muscle strength and body composition, and should be prescribed structured resistance training alongside medication. (neobesitysociety.org) OASIS 4 also fed the next round of marketing and prescribing arguments. Post hoc analyses presented at ObesityWeek 2025 linked larger weight loss with better blood sugar, blood pressure, and lipid measures, while Novo Nordisk argued oral semaglutide produced outcomes comparable to injected semaglutide in an indirect comparison. (appliedclinicaltrialsonline.com) The new version broadens access for patients who would take a daily pill but not a weekly injection. It also leaves the core message unchanged: the medicine still works as part of a longer program of diet, activity, monitoring, and muscle-preserving exercise. (ajmc.com)
